[Thyroid status in anemic pregnant women under conditions of endemic goiter]. [Article in Russian] Zel'tser me



Download 343.45 Kb.
Page1/6
Date13.06.2017
Size343.45 Kb.
#20755
  1   2   3   4   5   6
[Thyroid status in anemic pregnant women under conditions of endemic goiter].

[Article in Russian]



Zel'tser ME, Mezinova NN, Kobzar' NN, Bazarbekova RB, Nazyrov AT, Kim GG, Nurbekova AA, Nugmanova MI.

Abstract

Anemia is a highly prevalent condition among pregnant women in the Republic of Kazakhstan. The causes of this anemia are not quite clear, as is the problem of resistance of this type of anemia to therapy with iron preparations. The authors propose that this may be explained by the fact that many regions of the Republic are foci of endemic goiter, because tentative studies indicate a relationship between endemic goiter and hypothyrosis. The present study was aimed at examination of the thyroid status in pregnant women suffering from anemia in the town of Alma-Ata, a region endemic for goiter. Altogether 120 anemic pregnant women were examined, 60 of these with goiter and 60 without it. Control group consisted of 20 healthy pregnant women. Clinical and ultrasonic examinations, puncture biopsy of the thyroid, measurements of blood levels of TTH, total and free triiodothyronine and thyroxin, thyroxin-binding globulin, as well as of peripheral blood red cell counts, levels of hemoglobin, serum iron, assessment of total iron-binding capacity of the serum and saturation coefficient, were carried out. Healthy pregnant women from a focus of endemic goiter were found to represent a group at risk of anemia in the third pregnancy trimester. In anemic pregnant women endemic goiter aggravated anemia. Chronic iodine deficiency is conductive to formation in pregnant women of subclinical hypothyrosis whose severity increased in the presence of anemia, more so if anemia is paralleled by goiter.

PMID:

7899433


[PubMed - indexed for MEDLINE]

Hypothyroidism and Iron: Anemia and Hemochromatosis

The relationship between hypothyroidism and iron levels


By Mary Shomon, About.com Guide

Updated July 03, 2008

About.com Health's Disease and Condition content is reviewed by our Medical Review Board

See More About:



  • fatigue

  • anemia

  • hypothyroidism symptoms

  • hemachromatosis

  • hemochromatosis
Ads

Iron therapySimplified decision guide for treating iron deficiency anemiaMonofer.com

Great start to the dayKelloggs Corn Flakes Breakfast Add fruits and nuts to corn flakeswww.greatstartgreatday.co.in

Yoga During Pregnancy.LifeCell Brings You Prenatal Yoga. Get your Free Copy. Register!Lifecellinternational.com/Register

Thyroid Disease Ads


  • Thyroid Disease Symptoms

  • Thyroid Symptoms

  • Low Thyroid Symptoms

  • Iron Rich Foods Anemia

  • Symptoms of Thyroid Disease

Conditions related to iron levels in the blood are more common with hypothyroidism than in the average population, according to researchers.

Iron-deficiency anemia (insufficient iron) is more common in people with hypothyroidism. Symptoms or signs of anemia include:



  • Feeling tired or weak

  • Pale appearance to the lining of lower eyelids

  • palpitations, fast or irregular heart beat.

  • faintness and breathlessness.

  • hair loss.

  • bruising that occurs without reason

  • dizziness

  • long or unusually heavy menstrual periods

Anemia is diagnosed using a comprehensive iron panel blood test.

In addition to your doctor's recommendations regarding treatment for anemia and any suggested iron supplementation, you can also consider the following recommendations



  • Eat more foods that are good sources of iron.

  • Help your body absorb iron better by eating foods high in vitamin C.

  • Red meat can supply iron, but also helps your body absorb iron from other foods.

  • Limit your use of tea, except herbal teas.

  • Increase dietary fiber to prevent constipation.

Hemochromatosis is less common, but more frequently seen in people with hypothyroidism Symptoms of hemochromatosis include:

  • chronic fatigue

  • arthritis-like pain in joints, in particular, the middle two fingers

  • loss of libido (sex drive), impotence

  • early absence of menstrual periods

  • changes in skin color, yellowish, bronze, grey, olive

  • redness in the palms

  • abdominal pain

  • shortness of breath

  • heart arrhythmia

  • depression

  • elevated blood sugar

Hemochromatosis is not easy to diagnose, as it is not revealed in routine blood work so doctors need to request specific tests to diagnose it.

Treatment for hemochromatosis is a doctor-supervised program of giving blood, known as phlebotomy.

A detailed article on Hypothyroidism and Iron Levels is featured online.

CHAPTER 34 ANEMIA OF ENDOCRINE DISORDERS


Posted by medtextfree on December 27, 2011 in Hematology

CHAPTER 34 ANEMIA OF ENDOCRINE DISORDERS


Williams Hematology

CHAPTER 34 ANEMIA OF ENDOCRINE DISORDERS

ALLAN J. ERSLEV
Anemia of Pituitary Deficiency
Anemia of Thyroid Dysfunction
Anemia of Adrenal Dysfunction
Anemia of Gonadal Dysfunction
Anemia of Pregnancy
Anemia of Parathyroid Dysfunction
Anemia of Pancreatic Dysfunction
Chapter References

The hormones released by specific endocrine organs all play a role in modulating the rate of red cell production. The mechanisms involved vary greatly, and current interest in unraveling single actions have been replaced by attempts to integrate the actions of multiple hormonal-like growth factors and cytokines on the sequential proliferation and differentiation of red cell precursors. Consequently, the discussion in this chapter of anemias caused by a deficiency of a single traditional hormone is by necessity more historic than current.

Acronyms and abbreviations that appear in this chapter include: ACTH, adrenocorticotrophic hormone; 2,3-BPG, 2,3-bisphosphoglycerate; TSH, thyroid-stimulating hormone.

Numerous growth factors and cytokines are involved in the regulation and function of the erythropoietic tissue (see Chap. 14). Some are autocrine and released by the same cells on which they are acting, some are paracrine and released by neighboring cells, and some are endocrine and released from distant tissue and carried by blood to their target cells. The latter are traditionally designated hormones, and the effect on red cell production of altered hormone levels in blood due to endocrine tissue dysfunction is described here.1,2 The effect of the renal hormone erythropoietin is covered in Chap. 33.


ANEMIA OF PITUITARY DEFICIENCY
Hypophysectomy in the experimental animal is regularly followed by the development of moderately severe erythroid hypoplasia and anemia.3,4 In rats, the selective removal of the posterior or intermediate lobe does not cause anemia,5 and it is generally assumed that the pathogenesis of the anemia is related to the absence of anterior lobe hormones, which in turn modulate renal erythropoietin production.6 Of these, TSH is probably of most importance, since the anemia of hypophysectomy is very similar to the anemia of thyroidectomy.7 Nevertheless, it is claimed that the rate of red cell production in hypophysectomized animals is restored to normal only if the administration of TSH is supplemented by ACTH8 or if the administration of thyroid hormone is supplemented by both glucocorticoids and androgens.3 It has been proposed repeatedly that the pituitary gland produces a specific erythropoietic hormone,9,10 but the therapeutic effectiveness of target organ hormones alone is not in accord with such a possibility. Growth hormone has been shown to be capable of stimulating red cell production in vitro,11 an effect possibly mediated by insulin-like growth factor,12 but whether this effect is of physiologic significance remains unclear.13 The same holds true for the hypothetical effect of the hypothalamus on red cell production. It has been claimed that hypothalamic injury may affect erythropoietin release,14 the rate of red cell production,15 or both,16 and it has been proposed that these effects are mediated via the hypophysis. However, the experimental data provided in support of this hypothesis are unimpressive.15,16
In human subjects, hypophyseal dysfunction or hypophyseal ablation is often associated with leukopenia and is regularly accompanied by a normochromic and normocytic anemia. The red cell life span is normal, but marrow examination and ferrokinetic studies disclose moderate hypoplasia and relative marrow failure.17,18 Replacement therapy with a combination of thyroid, adrenal, and gonadal hormones usually corrects the anemia.19,20 It is probable that treatment with recombinant human erythropoietin would also do so.
ANEMIA OF THYROID DYSFUNCTION
In 1881, Charcot21 first recognized that cretins and patients with myxedema were anemic. At about the same time, the great Swiss surgeon Kocher22 reported that thyroidectomy also is followed by a reduction in the red cell count. The character of this type of anemia has been a source of debate ever since, and it has been variously described as normocytic, microcytic, or macrocytic.23 Studies have clarified the pathogenesis by separating the component caused by a lack of thyroid hormone from the components caused by complicating deficiencies of iron, vitamin B12, or folic acid.24,25,26 The rate of red cell production in experimental animals increases after the administration of thyroxin, triiodothyronine, or desiccated thyroid27,28 and decreases after thyroidectomy.29,30 These erythropoietic responses appear to be quite appropriate, since the need for circulating red cells depends on the cellular requirements for oxygen, which in turn are influenced by thyroid hormones.23,31,32 Nevertheless, it has also been proposed that the thyroid hormones have a noncalorigenic effect on red cell production.33 Studies of the influence of thyroid hormones on in vitro erythropoiesis have shown that both calorigenic T3 and T4 and noncalorigenic rT3 potentiate the effect of erythropoietin on the formation of erythroid colonies34,35 or increasing hypoxia-induced production of erythropoietin.36 This effect appears to be mediated by burst-promoting factors released by activated lymphocytes37 and/or by receptors with b2-adrenergic properties.37 Anemia observed in thyroidectomized animals conforms to both mechanisms by being normochromic and normocytic and associated with reticulocytopenia and hypoplasia of the erythropoietic tissue in the marrow. The red cell life span is normal, and ferrokinetic studies indicate the existence of a hypofunctioning but effective marrow.38
Anemia observed in human subjects with myxedema or other hypothyroid conditions is not always this clear-cut, since the condition may be complicated by nutritional deficiencies. However, many hypothyroid patients have a hypoplastic anemia that is unresponsive to therapy with iron, vitamin B12, or folic acid and is very similar to the form of anemia observed in thyroidectomized animals.23,24,39 The degree of anemia is mild to moderate, with a hemoglobin concentration rarely less than 8 to 9 g/dl. The corresponding decrease in erythroid marrow activity is frequently too small to be morphologically demonstrable.40 Ferrokinetic studies show a decrease in the turnover of plasma and red cell iron, a decrease that also may be so small that it is first recognized when compared with values obtained after thyroid replacement therapy.41,42 As in hypothyroid animals, the red cell life span and the rate of red cell utilization of iron are normal. The degree of anemia does not always reflect the reduction in marrow activity and the size of the red cell volume, since the plasma volume is decreased in hypothyroid patients.43 This may result in a temporary aggravation of apparent anemia after thyroid replacement therapy, since the plasma volume will be restored to normal before the red cell volume. Although normochromic and normocytic anemia must be considered the characteristic form of anemia of hypothyroidism, the most frequent type of anemia observed is a microcytic, hypochromic anemia caused by iron deficiency.23,44 In hypothyroid women, menorrhagia is a frequent complication and may explain adequately the lack of iron. However, even in men, iron is in short supply either because of the histamine-refractory achlorhydria, which is present in about 50 percent of anemic patients,45 or possibly because of intestinal malabsorption of iron.46,47 Macrocytosis is frequently identified with anemia of hypothyroidism.23,39 However, when a substantial increase in the mean corpuscular volume occurs, it is usually caused by a megaloblastic erythropoiesis owing to vitamin B12 or folic acid deficiency.24 In hypothyroid patients, the incidence of true pernicious anemia with gastric atrophy and intrinsic factor deficiency appears to be unusually high.48,49,50 This has led to interesting but still inconclusive speculations on the effect of cross-reacting autoantibodies against thyroglobulins and intrinsic factor or gastric parietal cells.51,52,53 This may be of special etiologic importance for Graves’ disease and Hashimoto’s thyroiditis, both autoimmune disorders. However, in a study of eight patients with coexisting megaloblastic anemia and hypothyroidism, it was concluded that all eight, rather than having vitamin B12 deficiency, had folic acid deficiency from either poor dietary intake of folic acid or intestinal malabsorption.26
Despite the direct and indirect erythropoietic effect of thyroid hormones, patients with hyperthyroidism or thyrotoxicosis rarely have elevated hemoglobin concentrations or hematocrit percentages43,54 and may even be moderately anemic.55,56 This absence of an expected secondary polycythemia has been explained by assuming that an increased cardiac output and rate of tissue perfusion meet the increased tissue requirements for oxygen. Conflicting data have been presented as to the effect of thyroid hormone in vitro on the intracellular concentration of 2,3-BPG and, in turn, the oxygen affinity of hemoglobin.57 So far, however, direct studies of hyperthyroid patients do not suggest the presence of enhanced oxygen transport to the tissues.58 It actually seems more likely that the absence of an overt secondary polycythemia is due to hemodilution. Direct measurements of the size of the red cell volume,43 the erythroid activity of the marrow,40 and the turnover of plasma and red cell iron54 show them to be above normal. If it were not for the concomitant increase in plasma volume, these patients would have elevated hemoglobin and hematocrit levels. Studies of the red cell life span in patients with thyrotoxicosis suggest a moderate shortening in red cell survival,59 possibly reflecting an autoimmune etiology with the production of anti–red-cell antibodies.60 In a few cases, severe hyperthyroidism has been found to be associated with anemia and abnormal iron utilization, apparently reflecting ineffective red cell production,44 or the production of erythropoietin-directed antibodies.61 The institution of radioiodine therapy results in a reduction in the size of the red cell volume to normal but only a slight change in the hematocrit.
ANEMIA OF ADRENAL DYSFUNCTION
Adrenalectomy in experimental animals causes a mild anemia responsive to therapy with adrenal glucocorticoids or erythropoietin.17,29,62 A similar type of normochromic, normocytic anemia has been observed in Addison’s disease,17,63 but because of the concomitant reduction in plasma volume, the hemoglobin concentration and the hematocrit percentage do not reflect the true decrease in red cell volume. The character of this type of anemia and the erythropoietic effect of physiologic amounts of ACTH or adrenal cortical hormones are still unclear, possibly because the changes involved are too small for adequate study. When administered in pharmacologic amounts, these hormones appear to cause mild erythrocytosis64 of about the same magnitude as that observed in Cushing’s disease65,66 and occasionally in Bartter’s syndrome67 and pheochromocytoma.68 However, whether this is mediated via release of renal erythropoietin or by direct action on the erythropoietic cells in the marrow is unknown.69
ANEMIA OF GONADAL DYSFUNCTION
The erythropoietic effect of androgens in both physiologic and pharmacologic dosages is well recognized and extensively utilized in the treatment of patients with various types of refractory anemia. Castration of the male experimental animal causes a decrease in the rate of red cell production until the hemoglobin concentration and the red cell volume become stabilized at levels approximately the same as those of the normal female.70,71 In sexually mature human males, the hemoglobin level is 1 to 2 g/dl higher than the level observed in males during childhood, advanced age, orchiectomy, or gonadal hypofunction. Under those circumstances, the hemoglobin level is similar to that of the normal human female.72,73,74
In pharmacologic doses androgens have been shown to stimulate red cell production75,76 by increasing the production of erythropoietin77 and by enhancing the effect of erythropoietin on the marrow.78 These actions have been attributed to two isomeric metabolites formed by the reduction of a 4-5 double bond. The 5a-H isomer is androgenic and believed to cause a release of erythropoietin from the kidney.79 The 5b-H isomer is not androgenic or erythropoietinogenic but is believed to cause inactive marrow stem cells to enter an erythropoietin-responsive phase.80
Before being replaced by recombinant human erythropoietin in the treatment of anemia of renal failure, androgens were used extensively.81,82 Even now, androgens may enhance the effect of erythropoietin and reduce the cost of such therapy.83
Studies on the effect of physiologic doses of estrogens suggest that these hormones cause a slight suppression of red cell production.83 In large doses, estrogens have been shown to cause the development of moderately severe anemia,84,85 but it has not been resolved whether this is caused by suppressed erythropoietin production85 or by inhibition of the progenitor cell action of erythropoietin.86 Inhibin and activin, two glycoprotein hormones released by gonadal cells in both male and female, have been shown in vitro to have an effect on human erythroid progenitor cells.87,88,89 The physiologic significance of these observations is still unknown.
Human placental lactogen and sheep prolactin have been shown to have erythropoietic activity in the mouse.90 It has been proposed that human placental lactogen is in part responsible for the stimulation of red cell production in pregnancy.91
ANEMIA OF PREGNANCY
Although pregnancy is not an endocrine disorder, it is associated with a mild anemia, presumably caused by changes in the hormonal environment.92 Studies of pregnant mice have shown that, despite a progressive decrease in the hematocrit, the red cell volume, erythropoietin secretion, and rate of red cell production increase during pregnancy.90 Placental lactogen, which is erythropoietically active in the mouse,92 may in part be responsible for the erythropoietic stimulation, but the hormonal mechanisms underlying both the increase in red cell volume and the even more pronounced increase in plasma volume are not precisely known.
In humans, anemia in pregnancy is most often aggravated by dietary restrictions93 and a concomitant iron deficiency.94,95 In a smaller number of cases, folic acid deficiency may also play a pathogenetic role,96 and it seems appropriate to give every pregnant woman preventive iron and folic acid supplements. However, even in the well-cared-for pregnant woman, anemia becomes manifest at about the eighth week of pregnancy, progresses slowly until the thirty-second to thirty-fourth week, and is then stable until it rather suddenly improves just before delivery.97,98 It is moderate in severity, with hemoglobin concentrations rarely below 10 g/dl, and studies of the red cell volume have shown it to be a dilution anemia.97,98 There has been an obvious reluctance to use radioactive tracers to measure red cell and plasma volume in early pregnancy. However, using a nonradioactive biotin technique,99 it has been shown that there is a gradual increase in red cell volume beginning before the twelfth week of pregnancy. This early increase is not associated with measurable changes in the concentration of serum transferrin receptors, reticulocyte counts, or erythropoietin titers.99,100 However, in the second and third trimester, erythrokinetic studies using both radioactive iron101 and serum transferrin receptor concentrations100 have shown an increased erythropoietic activity. The associated changes in reticulocyte counts, serum ferritin concentrations, and erythropoietin titers are small and difficult to detect102 but in some studies quite significant.103,104 Despite the increase in red cell volume, the hemoglobin concentration falls as a consequence of an even greater increase in plasma volume. The total increase in red cell volume during pregnancy is about 20 percent, while the increase in plasma volume is about 30 percent. The increase in plasma volume can probably be explained on the basis of an increase in the size of the uterine vascular bed, with a shift of fluid from extravascular to vascular space.
The induction of this hypervolemia creates a low-viscosity erythrocytosis, which promotes oxygen transport to the tissues. Although the hemoglobin concentration is decreased, the hypervolemic state ensures the pregnant uterus of an excellent blood perfusion and oxygen supply.
ANEMIA OF PARATHYROID DYSFUNCTION
Primary hyperparathyroidism is occasionally105,106 associated with anemia that disappears after parathyroidectomy.107,108 Similarly, it has been reported that parathyroidectomy in chronic renal disease often results in some improvement in the anemia,109,110 and it has been suggested that the parathyroid hormone may be a toxin that can suppress normal red cell production.111,112 However, other studies have not supported this suggestion.112,113,114,115 These suggest that primary or secondary hyperparathyroidism, when associated with suppressed red cell production, acts by causing either renal calcification with reduction in erythropoietin formation or marrow sclerosis with reduction in erythroid proliferation.116
ANEMIA OF PANCREATIC DYSFUNCTION
Although insulin and the insulin-like growth factors I and II appear to be involved in expanding the red cell mass after treatment with growth hormones, there is little evidence for the notion that insulin is an erythropoietic agent.119,120
CHAPTER REFERENCES

1.
Adamson JW, Popovic WJ, Brown JE: Hormonal control of erythropoiesis, in Hematologic Cell Differentiation, edited by DW Golde, MJ Cline, D Metcalf, pp 53–67. Academic, New York, 1978.

2.
Orwoll FS, Orwoll RL: Hematologic abnormalities in patients with endocrine and metabolic disorders. Hematol Oncol Clin North Am 1:261, 1987.

3.
Crafts RC, Meineke HA: The anemia of hypophysectomized animals. Ann NY Acad Sci 77:501, 1959.

4.
Gordon AS: Endocrine influences upon the formed elements of blood and blood forming organs. Prog Hormone Res 10:339, 1954.

5.
Van Dyke DC, Garcia JF, Simpson ME, et al: Maintenance of circulating red cell volume in rats after removal of the posterior and intermediate lobes of the pituitary. Blood 7:1017, 1952.

6.
Peschle C, Rappaport IA, Magli MC, et al: Role of hypophysis in erythropoietin production during hypoxia. Blood 5:1117, 1978.

7.
Crafts RC: The similarity between anemia induced by hypophysectomy and that induced by a combined thyroidectomy and adrenalectomy in adult female rats. Endocrinology 53:465, 1953.

8.
Fisher JW, Crook JJ: Influence of several hormones on erythropoiesis and oxygen consumption in the hypophysectomized rat. Blood 19:557, 1962.

9.
Contopoulos AN, Simpson ME, Van Dyke DC, et al: The pituitary erythropoietic factor. Anat Rec 118:290, 1954.

10.
Lindeman R, Trygstad O, Halvorsen S: Pituitary control of erythropoiesis. Scand J Haematol 6:77, 1969.

11.
Golde DW, Bersch N, Li CH: Growth hormone: Species specific stimulation of erythropoiesis in vitro. Science 196:1112, 1977.

12.
Merchav S, Tatarsky I, Hochberg Z: Enhancement of erythropoiesis in vitro by human growth hormone is mediated by insulin-like growth factor I. Br J Haematol 70:267, 1988.

13.
Jepson JH, McGarry EE: Hemopoiesis in pituitary dwarfs treated with human growth hormone and testosterone. Blood 39:238, 1972.

14.
Halvorsen S: Effect of hypothalamic stimulation on erythropoiesis and on the production of erythropoiesis-stimulating factors in intact and nephrectomized rabbits. Ann NY Acad Sci 149:88, 1968.

15.
Feldman S, Rachmilewitz EA, Izak G: The effect of central nervous system stimulation on erythropoiesis in rats with chronically implanted electrodes. J Lab Clin Med 67:713, 1966.

16.
Mirand EA, Grace JT, Johnston GS, Murphy GP: Effect of hypothalamic stimulation on the erythropoietic response in the rhesus monkey. Nature 204:1163, 1964.

17.
Daughaday WH, Williams RH, Daland GA: The effect of endocrinopathies on the blood. Blood 3:1342, 1948.

18.
Degrossi OJ, Houssay AB, Varela JE, Capalbo EE: Erythrokinetic studies in the anemia of thyroid and pituitary insufficiency, in Advances in Thyroid Research, edited by Pitt-Rivers R, p 410. Pergamon, New York, 1961.

19.
Ferrari E, Ascari E, Bossoto PA, Barosi G: Sheehan’s syndrome with complete bone marrow aplasia: Long-term results of substitution therapy with hormones. Br J Haematol 33:575, 1976.

20.
Sanders JE, Hawley J, Levy W, et al.: Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 87:3045, 1996.

21.
Charcot M: Myxedéme, cachexie pachydermique ou état cretinoide. Gaz Hop Paris 54:73, 1881.

22.
Kocher T: Ueber Kropfexstirpation und Ihre Folgen. Arch Klin Chir 29:254, 1883.

23.
Bomford R: Anemia in myxoedema and the role of the thyroid gland in erythropoiesis. Q J Med 7:495, 1938.

24.
Tudhope GR, Wilson GM: Anemia in hypothyroidism: Incidence, pathogenesis and response to treatment. Q J Med 29:513, 1960.

25.
Carpenter JT, Mohler DN Jr, Thorup OA Jr, Leavell BS: Anemia in myxedema, in Current Concepts in Hypothyroidism, edited by KR Crispell, p 147. Macmillan, New York, 1963.

26.
Hines JD, Halsted CH, Griggs RC, Harris JW: Megaloblastic anemia secondary to folate deficiency associated with hypothyroidism. Ann Intern Med 68:792, 1968.

27.
Donati RM, Warnecke MA, Gallagher NJ: Effect of triiodothyronine administration on erythrocyte radioiron incorporation in rats. Proc Soc Exp Biol Med 115:405, 1964.

28.
Chalet M, Coe D, Reissmann KR: Mechanisms of erythropoietic action of thyroid hormone. Proc Soc Exp Biol Med 123:443, 1966.

29.
Crafts RC: The effect of endocrines on the formed elements of the blood: I. The effects of hypophysectomy, thyroidectomy and adrenalectomy on the blood of the adult female rat. Endocrinology 29:596, 1941.

30.
Gordon AS, Kadow PC, Finkelstein G, Charipper HA: The thyroid and blood regeneration in the rat. Am J Med Sci 212:385, 1946.

31.
Jacobson LO, Goldwasser E, Gurney CW, et al: Studies on erythropoietin: The hormone regulating red cell production. Ann NY Acad Sci 77:551, 1959.

32.
Lucarelli G, Ferrari V, Rizzoli A, et al: The effect of triiodothyronine on the erythropoiesis: Assay in the normal, starved, polycythemic and nephrectomized rat. Biochim Biol Sper 5:475, 1966.

33.
Meineke HA, Crafts RC: Evidence for a noncalorigenic effect of thyroxin on erythropoiesis as judged by radio iron utilization. Proc Soc Exp Biol Med 117:520, 1964.

34.
Golde DW, Bersch N, Chopra IJ, Cline MJ: Thyroid hormones stimulate erythropoiesis in vitro. Br J Haematol 37:173, 1977.

35.
Popovic WJ, Brown JE, Adamson JW: The influence of thyroid hormones on in vitro erythropoiesis: Mediation by a receptor with beta adrenergic properties. J Clin Invest 60:907, 1977.

36.
Fandrey J, Pagel H, Frede S, Wolff M, Jelkmann W: Thyroid hormones enhance hypoxia-induced erythropoietin production in vitro. Exp Hematol 22:272, 1994.

37.
Daniak N, Sutter D, Kreczko S: L-triiodothyronine augments erythropoietic growth factor release from peripheral blood and bone marrow leukocytes. Blood 68:1289, 1986.

38.
Cline MJ, Berlin NI: Erythropoiesis and red cell survival in the hypothyroid dog. Am J Physiol 204:415, 1963.

39.
Horton L, Coburn RJ, England JM, et al: The haematology of hypothyroidism. Q J Med 45:101, 1975.

40.
Axelrod AR, Berman L: The bone marrow in hyperthyroidism and hypothyroidism. Blood 6:436, 1951.

41.
Kiely JM, Purnell DC, Owen CA Jr: Erythrokinetics in myxedema. Ann Intern Med 67:533, 1967.

42.
Finch CA, Deubelbeiss K, Cook JD, et al: Ferrokinetics in man. Medicine (Baltimore) 49:17, 1970.

43.
Muldowney FP, Crooks J, Wayne EJ: The total red cell mass in thyrotoxicosis and myxoedema. Clin Sci 16:309, 1957.

44.
Larsson SD: Anemia and iron metabolism in hypothyroidism. Acta Med Scand 157:349, 1967.

45.
Lerman J, Means JH: The gastric secretion in exophthalmic goiter and myxoedema. J Clin Invest 11:167, 1932.

46.
Pirzio-Biroli G, Bothwell TH, Finch CA: Iron absorption: II. The absorption of radio iron administered with standard meal. J Lab Clin Med 51:37, 1958.

47.
Donati RM, Fletcher JW, Wamecke MA, Gallagher NJ: Erythropoiesis in hypothyroidism. Proc Soc Exp Biol Med 144:78, 1973.

48.
Carmel R, Spencer CA: Clinical and subclinical thyroid disorders associated with pernicious anemia. Arch Intern Med 142:1465, 1982.

49.
Green ST, Ng JP, Chan-Lam D: Insulin dependent diabetes mellitus, myasthenia gravis, pernicious anemia, autoimmune thyroiditis and autoimmune adrenalitis in a single patient. Scott Med J 33:213, 1988.

50.
Petite J, Rosset N, Chapnis B, Jeannet M: Genetic factors predispose to autoimmune diseases: Study of HLA antigens in a family with pernicious anemia and thyroid diseases. Schweiz Med Wochenschr 117:2032, 1987.

51.
Irvine WJ, Davies SH, Delamore JW, Williams AW: Immunologic relationship between pernicious anemia and thyroid disease. Br Med J 12:454, 1962.

52.
Markson JL, Moore JM: Thyroid antibodies in pernicious anemia. Br Med J 12:1352, 1962.

53.
Ardeman S, Chanarin I, Krafchik B, Singer W: Addisonian pernicious anemia and intrinsic factor antibodies in thyroid disorders. Q J Med 35:421, 1966.

54.
Donati RM, Warnecke MA, Gallagher NJ: Ferrokinetics in hyperthyroidism. Ann Intern Med 63:945, 1963.

55.
Rivlin RS, Wagner HN: Anemia in hyperthyroidism. Ann Intern Med 70:507, 1969.

56.
Perlman JA, Sternthal PM: Effect of 131I on the anemia of hyperthyroidism. J Chron Dis 36:405, 1983.

57.
Miller WW, Delivoria-Papadopoulos M, Miller LD, Oski FA: Oxygen releasing factor in hypothyroidism. JAMA 211:1824, 1970.

58.
Zaroulis CG, Kourides JA, Valeri CR: Red cell 2,3-diphosphoglycerate and oxygen affinity of hemoglobin in patients with thyroid disorders. Blood 52:181, 1978.

59.
McClellan JE, Donegan C, Thorup OA, Leavell BS: Survival time of the erythrocyte in myxedema and hyperthyroidism. J Lab Clin Med 51:91, 1958.

60.
Bouchou K, Andre M, Cathebras P, et al: Pathologie thyroidienne et syndromes auto-immuns multiples: Aspects clinique et immunogenetique aá-propos de 11 observations. Rev Med Interne 16:283, 1995.

61.
Jyo-Oshiro Y, Nomura S, Fukushima T, Tamai H, Fueki H, Osawa G: Primary hyperthyroidism induced erythropoietin-resistant anemia? Intern Med 36:903, 1997.

62.
Van Dyke DC, Contopoulos AN, Williams BS, et al: Hormonal factors influencing erythropoiesis. Acta Haematol (Basel) 11:203, 1954.

63.
Baez-Villasenor J, Rath CE, Finch CA: The blood picture in Addison’s disease. Blood 3:769, 1948.

64.
Fisher JW: Increase in circulating red cell volume of normal rats after treatment with hydrocortisone or cortico-sterone. Proc Soc Exp Biol Med 97:502, 1958.

65.
Platz CM, Knowlton AJ, Ragan C: The natural history of Cushing’s syndrome. Am J Med 13:597, 1952.

66.
Ross EJ, Marshall-Jones P, Friedman M: Cushing’s syndrome: Diagnostic criteria. Q J Med 35:149, 1966.

67.
Erkelens DW, Statius van Eps LWS: Bartter’s syndrome and erythrocytosis. Am J Med 55:711, 1973.

68.
Shulkin BL, Shapiro B, Sisson JC: Pheochromocytoma, polycythemia and venous thrombosis. Am J Med 83:773, 1987.

69.
Golde DW, Bersch N, Cline MJ: Potentiation of erythropoiesis in vitro by dexamethasone. J Clin Invest 57:57 1976.

70.
Steinglass P, Gordon AS, Charipper HA: Effect of castration and sex hormones on blood of the rat. Proc Soc Exp Biol Med 48:169, 1941.

71.
Crafts RC: Effect of hypophysectomy, castration and testosterone propionate on hemopoiesis in the adult male rat. Endocrinology 39:401, 1946.

72.
Hawkins WW, Speck E, Leonard VG: Variation of the hemoglobin level with age and sex. Blood 9:999, 1954.

73.
Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoaglund HC: Anemia after orchiectomy. Am J Hem 59:230, 1998.

74.
Matsumoto AM, Bremner WJ: Hypogonadism: Androgen therapy, in Current Therapy in Endocrinology and Metabolism, edited by DT Krieger, CW Bardin, pp 145–149. Dekker, Toronto, 1986.

75.
Kennedy BJ, Gilbertsen AS: Increased erythropoiesis induced by androgenic-hormone therapy. N Engl J Med 256:719, 1957.

76.
Shahidi NT: Androgens and erythropoiesis. N Engl J Med 289:72, 1973.

77.
Alexanian R: Erythropoietin and erythropoiesis in anemic man following androgens. Blood 33:564, 1969.

78.
Singer JW, Samuels AJ, Adamson JW: The effect of steroids on in vitro erythroid colony growth: Structure/activity relationships. J Cell Physiol 88:127, 1976.

79.
Paulo LG, Fink GD, Roh BL, Fisher JW: Effects of several androgens and steroid metabolites on erythropoietin production in the isolated perfused dog kidney. Blood 43:39, 1974.

80.
Gorshein D, Hait WN, Besa EC, et al: Rapid stem cell differentiation induced by 19-nortestosterone decanoate. Br J Haematol 26:215, 1974.

81.
Eschbach JW, Adamson JW: Improvement in the anemia of chronic failure with fluoxymesterone. Ann Intern Med 78:527, 1973.

82.
Neff MS, Goldberg J, Slifkin RE, et al: A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 30:871, 1981.

83.
Gaughan WJ, Liss KA, Dunn SR, et al: A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 30:495, 1997.

84.
Dukes PP, Goldwasser E: Inhibition of erythropoiesis by estrogens. Endocrinology 69:21, 1961.

85.
Piliero SJ, Medici PT, Haber C: The interrelationships of the endocrine and erythropoietic systems in the rat with special reference to the mechanism of action of estradiol and testosterone. Ann NY Acad Sci 149:336, 1968.

86.
Jepson JH, Lowenstein L: Inhibition of the stem-cell action of erythropoietin by estradiol. Proc Soc Exp Biol Med 123:457, 1966.

87.
Yu J, Shao A, Lemas V, et al: Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature 330:765, 1987.

88.
Broxmeyer HE, Lu L, Coopers S, et al: Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin. Proc Natl Acad Sci USA 85:9062, 1988.

89.
Yu J, Shao A, Vaughan J, et al: Characterization of the potentiation effect of activin on human erythroid colony formation in vitro. Blood 73:952, 1989.

90.
Jepson JH, Lowenstein L: Hormonal control of erythropoiesis during pregnancy in the mouse. Br J Haematol 14:555, 1968.

91.
Berczi I, Wage E: Placental lactogen is a haemopoietic hormone. Br J Haematol 79:355, 1991.

92.
Letsky EA: Erythropoiesis in pregnancy. J Perinatal Med 23:39, 1995.

93.
Simmons WK, Simeon DT, Bramble D, Buffonge C, Gallagher P: Marked reduction of anemia during pregnancy over a 10-year period in Montserrat. Bull Pan Am Health Organ 30:18, 1996.

94.
Benjamin F, Bassen FA, Meyer LM: Serum levels of folic acid, vitamin B12 and iron in anemia of pregnancy. Am J Obstet Gynecol 96:310, 1966.

95.
Pritchard JA, Hunt CF: A comparison of the hematologic responses following the routine prenatal administration of intramuscular and oral iron. Surg Gynecol Obstet 106:516, 1958.

96.
Alperin JB, Hutchinson HT, Levin WC: Studies of folic acid requirements in megaloblastic anemia of pregnancy. Arch Intern Med 117:681, 1966.

97.
Low JA, Johnston EE, McBride RL: Blood volume adjustments in the normal obstetric patient with particular reference to the third trimester of pregnancy. Am J Obstet Gynecol 91:356, 1965.

98.
Pritchard JA: Changes in the blood volume during pregnancy and delivery. Anesthesiology 26:393, 1965.

99.
Weiner J, Cavill I, Williams GL, et al: Red cells in pregnancy: Erythropoietin and red cell mass in a sequential cohort study. Personal communication, 1992.

100.
Beguin Y, Lipscei G, Thoumsin H, Fillet G: Blunted erythropoietin production and decreased erythropoiesis in early pregnancy. Blood 78:89, 1991.

101.
Pritchard JA, Adams RH: Erythrocyte production and destruction during pregnancy. Am J Obstet Gynecol 79:750, 1960.

102.
Harstad TW, Mason RA, Cox SM: Serum erythropoietin quantitation in pregnancy using an enzyme-linked immunoassay. Am J Perinatol 9:233, 1992.

103.
Howells MR, Jones SE, Napier JA, et al: Erythropoiesis in pregnancy. Br J Haematol 64:595, 1986.

104.
Cotes PM, Canning CE, Lind T: Changes in immunoreactive erythropoietin during the menstrual cycle and normal pregnancy. Br J Obstet Gynaecol 90:304, 1983.

105.
Malette LE, Bilezikian JP, Heath DA, Aurbach GD: Primary hyperparathyroidism: Clinical and biochemical features. Medicine (Baltimore) 53:127, 1974.

106.
Abarca J, Trisonis C, Hamberser B, Granbers PO: Anaemia in primary hyperparathyroidism: Fantasy or reality? Ann Chir Gynaecol 74:74, 1985.

107.
Boxer M, Ellman L, Geller R, Wang CA: Anemia in primary hyperparathyroidism. Arch Intern Med 13:588, 1977.

108.
Falco JM, Guy JT, Smith RE, Mazzaferri EL: Primary hyperthyroidism and anemia. Arch Intern Med 136:887, 1976.

109.
Zingraff J, Drueke T, Marie P, et al: Anemia and secondary hyperparathyroidism. Arch Intern Med 138:1650, 1978.

110.
Kotzmann H, Abela C, Heindl J, et al: Effect of successful parathyroidectomy on hematopoietic progenitor cells and parameters of red blood cells in patients with primary hyperparathyroidism. Horm Metab Res 29:387, 1997.

111.
Massry SG: Is parathyroid hormone a uremic toxin? Nephron 19:125, 1977.

112.
Fujita Y, Inoue S, Horiguchi S, Kuki A: Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia. Miner Electrolyte Metab 21:50, 1995.

113.
Delwiche F, Garrity MJ, Powell JS, et al: High levels of the circulating form of parathyroid hormone do not inhibit in vitro erythropoiesis. J Lab Clin Med 102:613, 1983.

114.
Lutton JD, Solangi KB, Ibraham NG, et al: Inhibition of erythropoiesis in chronic renal failure: The role of parathyroid hormone. Am J Kidney Dis 3:380, 1984.

115.
McGonigle RJS, Wallin JD, Husserl F, et al: Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure. J Lab Clin Med 104:1016, 1984.

116.
Slackman N, Green AA, Naiman JL: Myelofibrosis in children with chronic renal insufficiency. J Pediatr 87:720, 1975.

117.
Ishimura E, Nishizawa Y, Okuno S, et al: Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol 11:83, 1998.

118.
James SH, Meyers AM: Microangiopathic hemolytic anemia as a complication of diabetes mellitus. Am J Med Sci 315:211, 1998.

119.
Sawada K, Krantz SB, Dessypris EN, et al: Human colony-forming-units-erythroid do not require accessory cells but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development. J Clin Invest 83:1701, 1989.

120.
Ten Have SM, van der Lely AJ, Lamberts SW: Increase in haemoglobin concentrations in growth hormone deficient adults during human recombinant growth hormone replacement therapy. Clin Endocrinol 47:565, 1997.
Books@Ovid
Copyright © 2001 McGraw-Hill
Ernest Beutler, Marshall A. Lichtman, Barry S. Coller, Thomas J. Kipps, and Uri Seligsohn
Williams Hematology

Like


Be the first to like this.

Tags: ANEMIA OF, CHAPTER 34, ENDOCRINE DISORDERS Permalink




Download 343.45 Kb.

Share with your friends:
  1   2   3   4   5   6




The database is protected by copyright ©ininet.org 2022
send message

    Main page